Trial Profile
Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study With Vacc-4x in Subjects Infected With HIV-1 Who Have Maintained an Adequate Response to ART.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vacc-4x (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms Reboost
- Sponsors Bionor Holding; Bionor Pharma
- 29 Jan 2018 According to a Bionor media release, Bionor Pharma changed its name to Bionor Holding.
- 28 Mar 2014 Results have been reported in a Bionor Pharma media release.
- 13 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov